Plasma C-MYC level manifesting as an indicator in progression of breast cancer

Biomark Med. 2019 Aug;13(11):917-929. doi: 10.2217/bmm-2019-0073. Epub 2019 May 30.

Abstract

Aim: To investigate whether plasma C-MYC level could be an indicator in clinical progression of breast cancer. Materials & methods: Plasma level of C-MYC expression was detected by quantitative real time PCR and the level of c-myc protein in breast cancer tissues was detected by immunohistochemistry. The expression level of C-MYC mRNA in supernatant of cancer cells culture was measured compared with the nonbreast cancer cells. Results: Plasma C-MYC level was significantly higher in patients with breast cancer than that in the controls, which associated with clinical stages, lymph node status, etc. Receiver operating characteristic curve analysis showed the sensitivity and specificity of plasma C-MYC level for diagnosis of breast cancer were 63.6 and 81.8%, respectively. The expression of c-myc protein in breast cancer tissues was associated with plasma C-MYC level, even C-MYC level in supernatant of cancer cells was elevated. Conclusion: Plasma C-MYC level might be a potential indicator in progression of breast cancer.

Keywords: breast cancer; circulating tumor DNA; diagnosis; indicator; prognosis; progression; q-PCR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers, Tumor / blood
  • Breast Neoplasms / blood*
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / pathology
  • Disease Progression
  • Female
  • Humans
  • Middle Aged
  • Prognosis
  • Proto-Oncogene Proteins c-myc / blood*
  • Proto-Oncogene Proteins c-myc / genetics

Substances

  • Biomarkers, Tumor
  • Proto-Oncogene Proteins c-myc